Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

An investigation into the prediction of the plasma concentration-time profile and its inter-individual variability for a range of flavin-containing monooxygenase substrates using a mechanistic physiologically based pharmacokinetic modelling approach.

Pilla Reddy V, Jones BC, Colclough N, Srivastava A, Wilson J, Li D.

Drug Metab Dispos. 2018 Jun 12. pii: dmd.118.080648. doi: 10.1124/dmd.118.080648. [Epub ahead of print]

PMID:
29895591
2.

Orally bioavailable and blood-brain-barrier penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice.

Karlin J, Allen J, Ahmad SF, Hughes G, Sheridan V, Odedra R, Farrington P, Cadogan EB, Riches LC, Garcia-Trinidad A, Thomason AG, Patel B, Vincent J, Lau A, Pike KG, Hunt TA, Sule A, Valerie NCK, Biddlestone-Thorpe L, Kahn J, Beckta JM, Mukhopadhyay N, Barlaam B, Degorce SL, Kettle J, Colclough N, Wilson J, Smith A, Barrett IP, Zheng L, Zhang T, Wang Y, Chen K, Pass M, Durant ST, Valerie K.

Mol Cancer Ther. 2018 May 16. pii: molcanther.0975.2017. doi: 10.1158/1535-7163.MCT-17-0975. [Epub ahead of print]

PMID:
29769307
3.

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).

Pike KG, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N, Davies NL, de-Almeida C, Degorce SL, Didelot M, Dishington A, Ducray R, Durant ST, Hassall LA, Holmes J, Hughes GD, MacFaul PA, Mulholland KR, McGuire TM, Ouvry G, Pass M, Robb G, Stratton N, Wang Z, Wilson J, Zhai B, Zhao K, Al-Huniti N.

J Med Chem. 2018 May 10;61(9):3823-3841. doi: 10.1021/acs.jmedchem.7b01896. Epub 2018 May 2.

PMID:
29683659
4.

Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity.

Lonsdale R, Burgess J, Colclough N, Davies NL, Lenz EM, Orton AL, Ward RA.

J Chem Inf Model. 2017 Dec 26;57(12):3124-3137. doi: 10.1021/acs.jcim.7b00553. Epub 2017 Nov 21.

PMID:
29131621
5.

An Investigation into the Prediction of in Vivo Clearance for a Range of Flavin-containing Monooxygenase Substrates.

Jones BC, Srivastava A, Colclough N, Wilson J, Reddy VP, Amberntsson S, Li D.

Drug Metab Dispos. 2017 Oct;45(10):1060-1067. doi: 10.1124/dmd.117.077396. Epub 2017 Aug 7.

PMID:
28784689
6.

Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.

Hennessy EJ, Chuaqui C, Ashton S, Colclough N, Cross DA, Debreczeni JÉ, Eberlein C, Gingipalli L, Klinowska TC, Orme JP, Sha L, Wu X.

ACS Med Chem Lett. 2016 Mar 21;7(5):514-9. doi: 10.1021/acsmedchemlett.6b00058. eCollection 2016 May 12.

7.

Interpreting physicochemical experimental data sets.

Colclough N, Wenlock MC.

J Comput Aided Mol Des. 2015 Sep;29(9):779-94. doi: 10.1007/s10822-015-9850-7. Epub 2015 Jun 9.

PMID:
26054297
8.

Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2.

Ward RA, Colclough N, Challinor M, Debreczeni JE, Eckersley K, Fairley G, Feron L, Flemington V, Graham MA, Greenwood R, Hopcroft P, Howard TD, James M, Jones CD, Jones CR, Renshaw J, Roberts K, Snow L, Tonge M, Yeung K.

J Med Chem. 2015 Jun 11;58(11):4790-801. doi: 10.1021/acs.jmedchem.5b00466. Epub 2015 May 28.

PMID:
25977981
9.

Using quantitative structure activity relationship models to predict an appropriate solvent system from a common solvent system family for countercurrent chromatography separation.

Marsden-Jones S, Colclough N, Garrard I, Sumner N, Ignatova S.

J Chromatogr A. 2015 Jun 12;1398:66-72. doi: 10.1016/j.chroma.2015.04.020. Epub 2015 Apr 17.

PMID:
25931379
10.

Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.

Kettle JG, Ballard P, Bardelle C, Cockerill M, Colclough N, Critchlow SE, Debreczeni J, Fairley G, Fillery S, Graham MA, Goodwin L, Guichard S, Hudson K, Ward RA, Whittaker D.

J Med Chem. 2015 Mar 26;58(6):2834-44. doi: 10.1021/acs.jmedchem.5b00098. Epub 2015 Mar 12.

PMID:
25738750
11.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL.

J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1.

PMID:
25271963
12.

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).

Ward RA, Anderton MJ, Ashton S, Bethel PA, Box M, Butterworth S, Colclough N, Chorley CG, Chuaqui C, Cross DA, Dakin LA, Debreczeni JÉ, Eberlein C, Finlay MR, Hill GB, Grist M, Klinowska TC, Lane C, Martin S, Orme JP, Smith P, Wang F, Waring MJ.

J Med Chem. 2013 Sep 12;56(17):7025-48. doi: 10.1021/jm400822z. Epub 2013 Aug 30.

PMID:
23930994
13.

Biophysical methods in drug discovery from small molecule to pharmaceutical.

Holdgate G, Geschwindner S, Breeze A, Davies G, Colclough N, Temesi D, Ward L.

Methods Mol Biol. 2013;1008:327-55. doi: 10.1007/978-1-62703-398-5_12.

PMID:
23729258
14.

The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach.

Allen JV, Bardelle C, Blades K, Buttar D, Chapman L, Colclough N, Dossetter AG, Garner AP, Girdwood A, Lambert C, Leach AG, Law B, Major J, Plant H, Slater AM.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5224-9. doi: 10.1016/j.bmcl.2011.07.047. Epub 2011 Jul 23.

PMID:
21835616
15.

Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer.

Bradbury RH, Hales NJ, Rabow AA, Walker GE, Acton DG, Andrews DM, Ballard P, Brooks NA, Colclough N, Girdwood A, Hancox UJ, Jones O, Jude D, Loddick SA, Mortlock AA.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5442-5. doi: 10.1016/j.bmcl.2011.06.122. Epub 2011 Jul 2.

PMID:
21782422
16.

Gradient elution in counter-current chromatography: a new layout for an old path.

Ignatova S, Sumner N, Colclough N, Sutherland I.

J Chromatogr A. 2011 Sep 9;1218(36):6053-60. doi: 10.1016/j.chroma.2011.02.052. Epub 2011 Apr 4.

PMID:
21470614
17.

A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.

Buttar D, Colclough N, Gerhardt S, MacFaul PA, Phillips SD, Plowright A, Whittamore P, Tam K, Maskos K, Steinbacher S, Steuber H.

Bioorg Med Chem. 2010 Nov 1;18(21):7486-96. doi: 10.1016/j.bmc.2010.08.052. Epub 2010 Sep 24.

PMID:
20869876
18.

High throughput solubility determination with application to selection of compounds for fragment screening.

Colclough N, Hunter A, Kenny PW, Kittlety RS, Lobedan L, Tam KY, Timms MA.

Bioorg Med Chem. 2008 Jul 1;16(13):6611-6. doi: 10.1016/j.bmc.2008.05.021. Epub 2008 May 10.

PMID:
18502135
19.

Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure.

Leach AG, Jones HD, Cosgrove DA, Kenny PW, Ruston L, MacFaul P, Wood JM, Colclough N, Law B.

J Med Chem. 2006 Nov 16;49(23):6672-82.

PMID:
17154498
20.

The effect of AET on the peripheral blood cells of the rabbit following gamma irradiation.

COLCLOUGH NV, HANNA C.

Arch Int Pharmacodyn Ther. 1963 May 1;143:8-16. No abstract available.

PMID:
14022181
21.

Toxicity and tolerance studies on AET.

HANNA C, COLCLOUGH NV.

Arch Int Pharmacodyn Ther. 1963 Apr 1;142:510-5. No abstract available.

PMID:
13952545

Supplemental Content

Loading ...
Support Center